| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 23 | 2025 | 2588 | 2.700 |
Why?
|
| Drug Resistance, Neoplasm | 9 | 2025 | 770 | 1.420 |
Why?
|
| Trastuzumab | 9 | 2025 | 145 | 0.980 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 1308 | 0.890 |
Why?
|
| Radiation-Sensitizing Agents | 4 | 2011 | 26 | 0.810 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 121 | 0.810 |
Why?
|
| NF-kappa B | 6 | 2011 | 438 | 0.800 |
Why?
|
| Curcumin | 3 | 2011 | 42 | 0.760 |
Why?
|
| Gene Expression Regulation, Neoplastic | 9 | 2021 | 1942 | 0.720 |
Why?
|
| Signal Transduction | 16 | 2025 | 4472 | 0.710 |
Why?
|
| Azadirachta | 2 | 2011 | 3 | 0.710 |
Why?
|
| Estrogen Receptor alpha | 5 | 2025 | 419 | 0.660 |
Why?
|
| Plant Extracts | 2 | 2011 | 131 | 0.630 |
Why?
|
| Apoptosis | 6 | 2019 | 1803 | 0.590 |
Why?
|
| Neuroblastoma | 4 | 2011 | 537 | 0.580 |
Why?
|
| Neoadjuvant Therapy | 6 | 2023 | 378 | 0.540 |
Why?
|
| Protein Kinase Inhibitors | 4 | 2025 | 572 | 0.520 |
Why?
|
| Antineoplastic Agents | 4 | 2021 | 1754 | 0.520 |
Why?
|
| Gamma Rays | 3 | 2011 | 41 | 0.510 |
Why?
|
| Gene Fusion | 1 | 2016 | 59 | 0.490 |
Why?
|
| Biomarkers, Tumor | 7 | 2023 | 1574 | 0.480 |
Why?
|
| Radiation, Ionizing | 2 | 2011 | 38 | 0.430 |
Why?
|
| Carrier Proteins | 2 | 2020 | 1013 | 0.420 |
Why?
|
| Cell Line, Tumor | 15 | 2025 | 3474 | 0.410 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 3 | 2025 | 79 | 0.410 |
Why?
|
| Gene Rearrangement | 1 | 2014 | 322 | 0.380 |
Why?
|
| Rosaceae | 1 | 2011 | 1 | 0.370 |
Why?
|
| Molecular Targeted Therapy | 4 | 2025 | 380 | 0.360 |
Why?
|
| Transcription Factor RelA | 1 | 2011 | 50 | 0.360 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2011 | 103 | 0.350 |
Why?
|
| Quinazolines | 3 | 2023 | 179 | 0.340 |
Why?
|
| Mice, Nude | 5 | 2025 | 707 | 0.340 |
Why?
|
| Superoxide Dismutase | 2 | 2010 | 170 | 0.340 |
Why?
|
| Digestive System | 1 | 2010 | 61 | 0.330 |
Why?
|
| Genes, p53 | 1 | 2010 | 213 | 0.320 |
Why?
|
| Receptors, Estrogen | 5 | 2021 | 714 | 0.310 |
Why?
|
| Sarcoma, Ewing | 1 | 2010 | 110 | 0.310 |
Why?
|
| Gene Expression Profiling | 5 | 2021 | 1783 | 0.300 |
Why?
|
| Gene Amplification | 3 | 2019 | 227 | 0.290 |
Why?
|
| Oncogene Proteins, Fusion | 2 | 2020 | 218 | 0.290 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2011 | 639 | 0.290 |
Why?
|
| Genomics | 1 | 2016 | 1577 | 0.280 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 626 | 0.260 |
Why?
|
| Female | 23 | 2025 | 68037 | 0.250 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2019 | 329 | 0.250 |
Why?
|
| Pancreatic Neoplasms | 1 | 2011 | 709 | 0.230 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2025 | 51 | 0.230 |
Why?
|
| Humans | 30 | 2025 | 126134 | 0.220 |
Why?
|
| Protein Kinases | 2 | 2016 | 322 | 0.220 |
Why?
|
| Neoplasm Transplantation | 3 | 2016 | 360 | 0.220 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2025 | 152 | 0.210 |
Why?
|
| Dose-Response Relationship, Radiation | 3 | 2011 | 57 | 0.190 |
Why?
|
| Cell Survival | 4 | 2021 | 836 | 0.190 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2025 | 291 | 0.190 |
Why?
|
| Mice | 10 | 2025 | 17619 | 0.190 |
Why?
|
| Prognosis | 5 | 2021 | 4697 | 0.190 |
Why?
|
| Carcinogenesis | 1 | 2025 | 342 | 0.180 |
Why?
|
| Remission Induction | 2 | 2020 | 298 | 0.180 |
Why?
|
| Brain Neoplasms | 1 | 2011 | 1218 | 0.180 |
Why?
|
| Linear Energy Transfer | 2 | 2011 | 9 | 0.180 |
Why?
|
| Plant Leaves | 2 | 2011 | 54 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 6 | 1 | 2021 | 48 | 0.170 |
Why?
|
| Cyclin-Dependent Kinase 4 | 1 | 2021 | 62 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2020 | 63 | 0.170 |
Why?
|
| Xenograft Model Antitumor Assays | 4 | 2021 | 931 | 0.160 |
Why?
|
| Mevalonic Acid | 1 | 2019 | 19 | 0.160 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2020 | 220 | 0.160 |
Why?
|
| Pyridones | 1 | 2020 | 135 | 0.160 |
Why?
|
| Pyridines | 1 | 2021 | 248 | 0.150 |
Why?
|
| Piperazines | 1 | 2021 | 251 | 0.150 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2021 | 253 | 0.150 |
Why?
|
| Cinnamates | 1 | 2018 | 16 | 0.150 |
Why?
|
| Brain | 1 | 2010 | 3031 | 0.150 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 130 | 0.150 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2018 | 92 | 0.150 |
Why?
|
| Animals | 10 | 2025 | 33230 | 0.140 |
Why?
|
| Lymphocytes | 1 | 2019 | 355 | 0.140 |
Why?
|
| Oncogene Addiction | 1 | 2017 | 3 | 0.140 |
Why?
|
| Indoles | 1 | 2018 | 200 | 0.130 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2019 | 753 | 0.130 |
Why?
|
| Transcription, Genetic | 3 | 2011 | 1381 | 0.130 |
Why?
|
| RNA-Binding Proteins | 1 | 2020 | 537 | 0.130 |
Why?
|
| Precision Medicine | 1 | 2019 | 346 | 0.130 |
Why?
|
| RNA, Small Interfering | 2 | 2016 | 656 | 0.120 |
Why?
|
| Gene Expression | 1 | 2020 | 1489 | 0.120 |
Why?
|
| Tumor Cells, Cultured | 2 | 2021 | 994 | 0.110 |
Why?
|
| Genomic Instability | 1 | 2016 | 238 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2017 | 473 | 0.110 |
Why?
|
| Ki-67 Antigen | 1 | 2014 | 102 | 0.110 |
Why?
|
| Cell Proliferation | 3 | 2018 | 2391 | 0.110 |
Why?
|
| Open Reading Frames | 1 | 2014 | 204 | 0.110 |
Why?
|
| Cell Separation | 1 | 2014 | 219 | 0.100 |
Why?
|
| Radiation Tolerance | 2 | 2011 | 58 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2021 | 1598 | 0.100 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 5107 | 0.100 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2014 | 284 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1901 | 0.100 |
Why?
|
| Treatment Outcome | 3 | 2023 | 12393 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2014 | 637 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-rel | 1 | 2011 | 3 | 0.090 |
Why?
|
| Flow Cytometry | 1 | 2014 | 758 | 0.090 |
Why?
|
| Aniline Compounds | 1 | 2011 | 18 | 0.090 |
Why?
|
| Aminoquinolines | 1 | 2011 | 35 | 0.090 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2011 | 10 | 0.090 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2011 | 33 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2020 | 1293 | 0.090 |
Why?
|
| I-kappa B Proteins | 1 | 2011 | 38 | 0.090 |
Why?
|
| Time Factors | 2 | 2011 | 6030 | 0.090 |
Why?
|
| Sequence Analysis, RNA | 1 | 2014 | 417 | 0.090 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2016 | 911 | 0.080 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2014 | 579 | 0.080 |
Why?
|
| Infrared Rays | 1 | 2010 | 19 | 0.080 |
Why?
|
| Cell Movement | 1 | 2014 | 846 | 0.080 |
Why?
|
| bcl-2-Associated X Protein | 1 | 2010 | 66 | 0.080 |
Why?
|
| Sequence Analysis, DNA | 1 | 2016 | 1739 | 0.080 |
Why?
|
| ErbB Receptors | 1 | 2011 | 286 | 0.080 |
Why?
|
| Fruit | 1 | 2011 | 231 | 0.080 |
Why?
|
| Telomerase | 1 | 2011 | 153 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2010 | 169 | 0.080 |
Why?
|
| DNA Primers | 1 | 2010 | 603 | 0.080 |
Why?
|
| Transfection | 1 | 2011 | 949 | 0.080 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 416 | 0.070 |
Why?
|
| Phenotype | 2 | 2016 | 4313 | 0.070 |
Why?
|
| RNA, Messenger | 2 | 2011 | 2552 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 1236 | 0.070 |
Why?
|
| Tamoxifen | 2 | 2020 | 344 | 0.070 |
Why?
|
| Mutation | 3 | 2025 | 5933 | 0.070 |
Why?
|
| MCF-7 Cells | 2 | 2018 | 207 | 0.070 |
Why?
|
| Polymerase Chain Reaction | 1 | 2010 | 1490 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1239 | 0.060 |
Why?
|
| Phosphorylation | 2 | 2021 | 1540 | 0.060 |
Why?
|
| Base Sequence | 1 | 2010 | 2773 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2011 | 746 | 0.060 |
Why?
|
| Oxidative Stress | 1 | 2010 | 753 | 0.060 |
Why?
|
| DNA | 1 | 2011 | 1430 | 0.060 |
Why?
|
| Models, Biological | 1 | 2010 | 1375 | 0.060 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 2 | 1 | 2025 | 39 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2016 | 3260 | 0.060 |
Why?
|
| Laminin | 1 | 2025 | 66 | 0.060 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 566 | 0.050 |
Why?
|
| Cytokines | 1 | 2009 | 1317 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2009 | 975 | 0.050 |
Why?
|
| Up-Regulation | 2 | 2016 | 829 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2010 | 4517 | 0.040 |
Why?
|
| Middle Aged | 4 | 2025 | 27402 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2020 | 87 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2020 | 102 | 0.040 |
Why?
|
| Dasatinib | 1 | 2020 | 48 | 0.040 |
Why?
|
| src-Family Kinases | 1 | 2020 | 89 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2020 | 73 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2020 | 79 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2020 | 372 | 0.040 |
Why?
|
| Breast | 1 | 2020 | 209 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2020 | 299 | 0.040 |
Why?
|
| Radiation Dosage | 2 | 2009 | 127 | 0.040 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 1 | 2019 | 167 | 0.040 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2019 | 377 | 0.040 |
Why?
|
| Heterografts | 1 | 2018 | 189 | 0.040 |
Why?
|
| G2 Phase Cell Cycle Checkpoints | 1 | 2016 | 8 | 0.030 |
Why?
|
| Estradiol | 1 | 2018 | 475 | 0.030 |
Why?
|
| Estrogens | 1 | 2018 | 423 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2020 | 1475 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2016 | 224 | 0.030 |
Why?
|
| Drug Design | 1 | 2016 | 154 | 0.030 |
Why?
|
| Cell Cycle | 1 | 2016 | 584 | 0.030 |
Why?
|
| DNA Damage | 1 | 2016 | 491 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2016 | 1011 | 0.030 |
Why?
|
| Reproducibility of Results | 1 | 2020 | 2877 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 56 | 0.020 |
Why?
|
| Aged | 2 | 2020 | 20078 | 0.020 |
Why?
|
| Cell Death | 1 | 2011 | 234 | 0.020 |
Why?
|
| DNA, Neoplasm | 1 | 2011 | 287 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 4433 | 0.020 |
Why?
|
| Genome, Human | 1 | 2016 | 1284 | 0.020 |
Why?
|
| Algorithms | 1 | 2016 | 1639 | 0.020 |
Why?
|
| Baculoviral IAP Repeat-Containing 3 Protein | 1 | 2009 | 5 | 0.020 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2009 | 11 | 0.020 |
Why?
|
| Inhibitor of Apoptosis Proteins | 1 | 2009 | 43 | 0.020 |
Why?
|
| Adult | 2 | 2020 | 30314 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2019 | 6582 | 0.020 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2009 | 248 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2011 | 666 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2011 | 1211 | 0.020 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2009 | 354 | 0.020 |
Why?
|
| Young Adult | 1 | 2019 | 9635 | 0.010 |
Why?
|